Sudoriferous (Sweat) Gland Disorders is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Sudoriferous (Sweat) Gland Disorders have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Sudoriferous (Sweat) Gland Disorders compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sudoriferous (Sweat) Gland Disorders overview
Sweat glands, also known as sudoriferous or sudoriparous glands, are small tubular structures of the skin that produce sweat. Sweat glands are a type of exocrine gland, which are glands that produce and secrete substances onto an epithelial surface by way of a duct. It is a skin disease caused by the blockage or inflammation of eccrine sweat glands
For a complete picture of PTSR and LoA scores for drugs in Sudoriferous (Sweat) Gland Disorders, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.